美国头颈癌手术的医院加价情况
这项横断面研究利用全国住院患者样本分析了2001至2011年间150275例头颈癌手术患者的医院加价情况,发现加价比率范围为0.8至8.7,平均为2.8,最高四分位医院平均加价为4.1。多变量分析显示,私立营利性医院、西部地区医院、西班牙裔种族、既往放疗、合并症和并发症与更高加价显著相关。医院市场集中度改变了营利状态与加价之间的关联。
要点
- 医院加价比率(收费与成本之比)范围为0.8至8.7,平均为2.8。
- 最高四分位加价医院更常见为大型、私立营利性医院,且较少为高手术量医院或位于竞争性市场。
- 私立营利性医院与加价显著升高相关(升高47.9%,95%CI 33.3%-64.2%)。
核心结论
- 头颈癌手术的医院加价存在广泛差异,25%的医院收费相对于成本增加4倍。
- 手术价格差异主要与医院营利状态相关。
- 这些数据提示需要提高透明度以解决医院定价差异。
研究设计与样本
- 横断面研究,使用全国住院患者样本识别2001至2011年间150275例因恶性上呼吸消化道肿瘤接受头颈癌手术的患者。
- 加价比率(收费与成本之比)作为连续和分类变量建模。
- 医院市场集中度使用可变半径赫芬达尔-赫希曼指数评估,数据来自2000、2003、2006和2009年医院市场结构文件。
- 数据分析时间为2019年5月至2019年7月。
主要发现
- 150275例患者平均年龄61.8岁(标准差12.6),104974例(70.0%)为男性。
- 医院加价比率范围为0.8至8.7,平均加价比率为2.8(95%CI 2.7-2.9)。
- 最低加价四分位医院平均加价比率为1.8(95%CI 1.8-1.9),最高加价四分位(极端加价)医院平均加价比率为4.1(95%CI 4.0-4.2)。
- 极端加价医院更多为大型医院(77.5% vs 66.6%)、私立营利性医院(19.0% vs 1.3%),较少为高手术量医院(21.0% vs 9.4%)或位于竞争性市场(64.4% vs 82.0%)。
- 术后并发症在极端加价医院更常见(22.7% vs 17.1%)。
关键数值与推荐
- 多变量分析中,加价显著升高与以下因素相关:私立营利性医院(升高47.9%,95%CI 33.3%-64.2%)、西部地区医院(升高25.5%,95%CI 12.6%-39.8%)、西班牙裔种族(升高9.8%,95%CI 4.4%-15.5%)、既往放疗(升高5.3%,95%CI 1.3%-9.4%)、合并症(升高3.5%,95%CI 1.7%-5.4%)和并发症(升高2.8%,95%CI 0.3%-5.4%)。
- 医院市场集中度改变了医院营利状态与加价之间的关联,在中等集中和集中(竞争较弱)市场中,营利性医院的加价更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Marked variation in hospital costs and payments is a target for health care reform efforts. Limited data exist to explain variability in prices for head and neck surgical procedures. OBJECTIVE: To characterize variations in hospital price markup for head and neck cancer surgery, and examine associations with market concentration and hospital for-profit status. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study, the Nationwide Inpatient Sample was used to identify 150 275 patients who underwent head and neck cancer surgery for a malignant upper aerodigestive tract neoplasm from 2001 to 2011. The markup ratio (charges to costs) was modeled as a continuous and categorical variable. Hospital market concentration was evaluated using a variable-radius Herfindahl-Hirschman Index from the 2000, 2003, 2006, and 2009 Hospital Market Structure files. Data were analyzed from May 2019 to July 2019. MAIN OUTCOMES AND MEASURES: Multivariable regression was used to evaluate associations between hospital and patient variables and hospital markup. RESULTS: There were 150 275 patients (mean [SD] age, 61.8 [12.6] years; 104 974 [70.0%] male) from 2001 to 2011 for whom hospital market information was available. Hospital markup ratios ranged from 0.8 to 8.7, with a mean markup ratio of 2.8 (95% CI, 2.7-2.9). Hospitals in the lowest markup ratio quartile had a mean markup ratio of 1.8 (95% CI, 1.8-1.9), while hospitals in the top markup ratio quartile (extreme markup) had a mean markup ratio of 4.1 (95% CI, 4.0-4.2). Extreme markup hospitals were more often large (77.5% vs 66.6%), private for-profit hospitals (19.0% vs 1.3%), and were less likely to be high-volume hospitals (21.0% vs 9.4%) or in competitive markets (64.4% vs 82.0%). Postoperative complications occurred more often in extreme markup hospitals (22.7% vs 17.1%). On multivariate analysis, a significantly higher markup was associated with private, for-profit hospitals (47.9%; 95% CI, 33.3%-64.2%), hospitals in the West (25.5%; 95% CI, 12.6%-39.8%), Hispanic race (9.8%; 95% CI, 4.4%-15.5%), prior radiation therapy (5.3%; 95% CI, 1.3%-9.4%), comorbidity (3.5%; 95% CI, 1.7%-5.4%), and complications (2.8%; 95% CI, 0.3%-5.4%). Hospital market concentration modified the association between hospital for-profit status and markup, with higher markups in for-profit hospitals in moderately concentrated and concentrated (less competitive) markets. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, there was wide variation in hospital markup for head and neck cancer surgery, with a 4-fold increase in charges relative to costs in 25% of hospitals. Variations in surgical price were primarily associated with hospital profit status. These data suggest that greater transparency is needed to address disparities in hospital pricing.
引用
- Miller JR, Frick KD, Gourin CG, et al. Hospital Markup in Head and Neck Cancer Surgery in the US. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36301556. doi:10.1001/jamaoto.2022.3340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。